SIMCERE ZAIMING HKEX Listing Application Lapses Upon Six-Month Expiry; Recorded Most Out-Licensing Transactions Among Chinese Biopharma Firms in 2025
NewTimeSpace News: The listing application filed by Simcere Zaiming Pharmaceutical Co., Ltd. with The Stock Exchange of Hong Kong Limited on 9 January 2026 has lapsed upon expiration of the six-month validity window. Morgan Stanley and China International Capital Corporation served as the original joint sponsors.
The Company is a biopharmaceutical enterprise concentrating on the research, development and commercialisation of innovative oncology medicines, covering a full value chain from drug discovery through manufacturing to commercial launch. Its marketed portfolio comprises five innovative medicines, including Endostar®, China’s first anti-angiogenic agent; Cosela®, the world-first myeloprotective agent for comprehensive bone marrow protection; and Erlitux®, the first domestically developed anti-EGFR monoclonal antibody in China. Four of the five commercialised products have been included in the National Reimbursement Drug List.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- METIS TECHBIO-P (07666.HK): Added as Hang Seng Composite Index Constituent, Effective 7 September
- SUNSHINE OIL (02012.HK): Subsidiary Holds 40% Stake in New Joint Venture to Build 6,000P Computing Power Centre
- CH GENERAL EDU (02175.HK): Target Company Unlikely to Meet 2026 Net Profit Target; Agreement in Principle to Reduce Acquisition Consideration
- PATEO (02889.HK): Acquires 20% Equity of Seagull Kitchen & Bath for RMB 800 Million and Becomes Controlling Shareholder, Constituting a Major Transaction
- XINXIN MINING(03833.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at CNY 249.42 million, YoY increase of 248.13%
